Phio Pharmaceuticals (PHIO) Fireside chat summary

Introduction and agenda

• The session focused on skin cancer, particularly cutaneous squamous cell carcinoma, and introduced key speakers with expertise in dermatology and biopharma innovation.

• Audience questions were encouraged and addressed in a dedicated Q&A segment.

Background and experience of the speaker

• Dr. R. Todd Plott is a board-certified dermatologist with 30 years of experience, specializing in complex skin conditions and skin cancers.

• Robert Bitterman leads a lean biopharma team with a track record in drug development and approvals.

Current industry trends

• Surgery remains the primary treatment for squamous cell carcinoma, but there is a need for less invasive alternatives.

• Monoclonal antibodies are used for advanced stages but have limited efficacy and significant adverse events.